

## TECHNICAL DATA SHEET

### CyFlow™ CD19 PE-DyLight™ 594 Anti-Hu; Clone LT19

**REF** CP837584

**For Research Use Only.  
Not for use in diagnostic or therapeutic procedures.**

### Specifications

<b>Antigen</b>	CD19
<b>Alternative Names</b>	B4
<b>Clone</b>	LT19
<b>Clonality</b>	monoclonal
<b>Format</b>	PE-DyLight™ 594
<b>Host / Isotype</b>	Mouse / IgG1
<b>Species Reactivity</b>	Human
<b>Negative Species Reactivity</b>	—
<b>Quantity</b>	100 tests
<b>Immunogen</b>	Daudi human Burkitt lymphoma cell line

### Specificity

The mouse monoclonal antibody LT19 recognizes CD19 antigen, a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.

#### Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany  
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: [info@sysmex-partec.com](mailto:info@sysmex-partec.com)

## Application

The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10<sup>6</sup> cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Other usages may be determined from the scientific literature.

## Storage Buffer

The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.

## Storage and Stability

<b>Storage</b>	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
<b>Stability</b>	Do not use after expiration date stamped on vial label.

## Background Information

CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell threshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.

## References

- Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15; 162(12):7088-94. < PMID: 10358152 >
- Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15; 99(2):584-9. < PMID: 11781242 >

---

### Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany  
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: [info@sysmex-partec.com](mailto:info@sysmex-partec.com)

- Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. *J Immunol.* 2003 Oct 1; 171(7):3697-704. < PMID: 14500668 >
- Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. *Blood.* 2005 Nov 15; 106(10):3567-74. < PMID: 16046525 >
- van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. *N Engl J Med.* 2006 May 4; 354(18):1901-12. < PMID: 16672701 >
- Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. *Arthritis Rheum.* 2007 Sep; 56(9):3057-69. < PMID: 17763445 >
- Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. *Int J Lab Hematol.* 2014 Apr; 36(2):165-71. < PMID: 24028768 >

---

The Safety Data Sheet for this product is available at [www.sysmex-partec.com/services](http://www.sysmex-partec.com/services).

This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or [outlicensing@lifetech.com](mailto:outlicensing@lifetech.com).

---

---

**Contact Information:**

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany  
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: [info@sysmex-partec.com](mailto:info@sysmex-partec.com)